These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 35972717)

  • 21. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comprehensive Review of Lemborexant to Treat Insomnia.
    Fuller MC; Carlson SF; Grant C; Berry V; Ivancich M; Cornett EM; Kaye AM; Viswanath O; Urits I; Shekoohi S; Kaye AD
    Psychopharmacol Bull; 2024 Mar; 54(1):43-64. PubMed ID: 38449475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orexin OX
    Jacobson LH; Chen S; Mir S; Hoyer D
    Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
    Shariq AS; Rosenblat JD; Alageel A; Mansur RB; Rong C; Ho RC; Ragguett RM; Pan Z; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():1-7. PubMed ID: 30576764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
    De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
    J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orexin antagonists for insomnia.
    Young J; Lee E; Lindblad AJ; Falk J
    Can Fam Physician; 2024 Mar; 70(3):183-184. PubMed ID: 38499379
    [No Abstract]   [Full Text] [Related]  

  • 29. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
    Connor KM; Mahoney E; Jackson S; Hutzelmann J; Zhao X; Jia N; Snyder E; Snavely D; Michelson D; Roth T; Herring WJ
    Int J Neuropsychopharmacol; 2016 Aug; 19(8):. PubMed ID: 26979830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs.
    Kumar A; Chanana P; Choudhary S
    Pharmacol Rep; 2016 Apr; 68(2):231-42. PubMed ID: 26922522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual orexin receptor antagonists for insomnia in youth with neurodevelopmental disorders: a case series and review.
    Besterman AD; Jeste SS
    Eur Child Adolesc Psychiatry; 2023 Mar; 32(3):527-531. PubMed ID: 34611728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment.
    Palagini L; Geoffroy PA; Balestrieri M; Miniati M; Biggio G; Liguori C; Menicucci D; Ferini-Strambi L; Nobili L; Riemann D; Gemignani A
    J Sleep Res; 2023 Aug; 32(4):e13825. PubMed ID: 36786121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
    Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
    Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders.
    Han Y; Yuan K; Zheng Y; Lu L
    Neurosci Bull; 2020 Apr; 36(4):432-448. PubMed ID: 31782044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder.
    Chepke C; Jain R; Rosenberg R; Moline M; Yardley J; Pinner K; Kumar D; Perdomo C; Filippov G; Atkins N; Malhotra M
    Postgrad Med; 2022 Apr; 134(3):316-325. PubMed ID: 35254948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daridorexant in Insomnia Disorder: A Profile of Its Use.
    Nie T; Blair HA
    CNS Drugs; 2023 Mar; 37(3):267-274. PubMed ID: 36754930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis.
    Xue T; Wu X; Li J; Chen S; Wang Z; Tan X; Wang Z; Zhang J
    Front Pharmacol; 2023; 14():1175372. PubMed ID: 37261282
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists-Daridorexant, Lemborexant, and Suvorexant: Part 1: Pharmacokinetic Profiles.
    Preskorn SH
    J Psychiatr Pract; 2022 Nov; 28(6):478-480. PubMed ID: 36355586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.